05:32 PM EDT, 04/15/2026 (MT Newswires) -- Robert I Blum, Director, President & CEO, on April 15, 2026, sold 7,500 shares in Cytokinetics ( CYTK ) for $490,350. Following the Form 4 filing with the SEC, Blum has control over a total of 419,496 common shares of the company, with 415,330 shares held directly and 4,166 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1061983/000106198326000035/xslF345X05/form4.xml